Role of intravenous levetiracetam in status migrainosus [5]

Journal of Headache and Pain

Volumn 8, Issue 2, 2007, Pages 143-144

  Farooq, Muhammad U ^a   Majid, Arshad ^a   Pysh, Joseph J ^a   Kassab, Mounzer Y ^b  

^a East Lansing   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; CLINICAL FEATURE; COMPLEX PARTIAL SEIZURE; DISEASE EXACERBATION; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; GENERALIZED EPILEPSY; HEADACHE; HUMAN; LETTER; MIGRAINE WITH AURA; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIGRAINE DISORDERS; PIRACETAM;

EID: 34249060225     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-007-0378-7     Document Type: Letter

References (7)

1. Niedermeyer E, Vining EP (1993) Migraine-triggered epilepsy. Clin Electroencephalogr 24:37-43
2. Rigo JM, Hans G, Nguyen L et al (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal gaba- and glycine-gated currents. Br J Pharmacol 136:659-672
3. Gillard M, Chatelain P, Fuks B (2006) Binding characteristics of levetiracetam to synaptic vesicle protein 2a (sv2a) in human brain and in cho cells expressing the human recombinant protein. Eur J Pharmacol 536:102-108
4. Brighina F, Palermo A, Aloisio A et al (2006) Levetiracetam in the prophylaxis of migraine with aura: A 6-month open-label study. Clin Neuropharmacol 29:338-342
5. Krusz JC (2001) Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 21:373
6. Gallai V, Alberti A, Rossi C et al (2003) An open label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J Headache Pain 4:92-96
7. Di Trapani G, Mei D, Vollono C et al (2004) Antiepileptic drugs in the treatment of headache: Neuroprotective effect or something else? J Headache Pain 5 [Suppl 2]:S117-S120